A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 815 participants.
Also called NCT07026968
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 815 participants
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Registry
-
NCT07026968
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07026968. Randomized; double masking; primary purpose treatment. Start 2025-06-20 (actual); primary completion 2026-10-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
- Intervention (Drug)
- Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
- Intervention (Drug)
- Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR
- Intervention (Drug)
- Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR
- Intervention (Drug)
- Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
- Lead sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07026968- Content hash
b17534c12d04b8458ed9409fce0f6b768fdbd9dda8ae665d9a87360957ff5efa